CASI Pharmaceuticals Inc (OQ:CASI)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 9620 Medical Center Drive, Suite 300
BEIJING BEJ 100025
Tel: N/A
Website: www.casipharmaceuticals.com
IR: See website
<
Key People
Wei-Wu He
Chairman of the Board, Chief Executive Officer
Wei Zhang
President, Principal Financial Officer
Chunhua Wang
Chief Operating Officer
Huang Hai
Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
Alexander A. Zukiwski
Executive Vice President, Chief Medical Officer
Kun Qian
Vice President, Controller
Wei Gao
General Counsel
Fuqiang Zhang
Chief Commercial Officer
 
Business Overview
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company's Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Financial Overview
For the nine months ended 30 September 2023, CASI Pharmaceuticals Inc revenues decreased 3% to $27M. Net loss applicable to common stockholders decreased 3% to $20.9M. Revenues reflect Lease income from a related party decrease from $60K to $0K. Lower net loss reflects Other income increase from $60K to $1.9M (income), Change in fair value of investment in eq decrease of 47% to $1.1M (expense), Interest (income) expense.
Employees: 224 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $26.74M as of Dec 31, 2023
Annual revenue (TTM): $42.26M as of Dec 31, 2023
EBITDA (TTM): -$26.03M as of Dec 31, 2023
Net annual income (TTM): -$40.42M as of Dec 31, 2023
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: N/A
Shares outstanding: 13,321,507 as of Sep 30, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.